Key result
Dexmedetomidine lowers heart rate by ~11 bpm in children with congenital heart disease.
Why the study?
Does dexmedetomidine administration cause significant haemodynamic changes in children with congenital heart disease undergoing cardiac procedures?
Meta-Analysis (n=408)
Does dexmedetomidine administration cause significant haemodynamic changes in children with congenital heart disease undergoing cardiac procedures?
Mean Difference: -11.25 (95% CI -15.24–-7.3)
p-value: p=<0.00001
Dexmedetomidine administration in children with congenital heart disease undergoing cardiac procedures is associated with small, clinically minimal decreases in heart rate and blood pressure, supporting its safety profile in this population.
Minimal hemodynamic effects support dexmedetomidine safety in pediatric congenital heart procedures; strengthens evidence for use in this population.
Introduction: Dexmedetomidine is frequently used in paediatric anaesthesia. This includes use in patients with CHD, but detailed analysis of haemodynamics after administration in these patients has not yet been published. We performed a systematic review and meta-analyses examining haemodynamic changes immediately after dexmedetomidine administration in patients with CHD. Methods: We conducted a systematic review of PubMed, Embase, and Medline from inception until May 31, 2024. Inclusion criteria were studies that contained children with CHD who received dexmedetomidine for a cardiac procedure and reported at least one haemodynamic variable before and after administration of dexmedetomidine. Exclusion criteria were studies of noncardiac procedures. We performed a meta-analysis on each haemodynamic variable that was reported by at least four studies. Results: We screened 5383 abstracts. We included 85 studies for review, and 16 studies were accepted for four meta-analyses (heart rate, 16 studies, n = 408; systolic blood pressure, 11 studies, n = 280; diastolic blood pressure, 10 studies, n = 276; mean arterial pressure, 5 studies, n = 130). Analysis of heart rate, systolic blood pressure, and diastolic blood pressure showed a statistically significant reduction ( p < 0.001), while there was no significant change in mean arterial pressure. The clinical difference was minimal with a decrease in heart rate of 11.3 beats per minute, and a decrease in systolic blood pressure/diastolic blood pressure of 5.9 and 6.2 mmHg, respectively. Heterogeneity was high in all analyses. Discussion: Dexmedetomidine is associated with small changes in heart rate, systolic blood pressure, and diastolic blood pressure in children with CHD. Further study is warranted.
No takes yet. Share an insight, caveat, or question.
Rose et al. (2025) conducted a meta-analysis in Congenital heart disease (n=408). Dexmedetomidine vs. Pre-administration baseline was evaluated on Change in heart rate (MD -11.25, 95% CI -15.24, -7.30, p=<0.00001). Dexmedetomidine administration in children with congenital heart disease was associated with a statistically significant but clinically minimal decrease in heart rate (mean difference -11.25 beats per minute).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: